Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report

Citation

Randhawa, M, Gaughran, G, Archer, C et al. 2019, 'Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report', World Journal of Clinical Oncology, vol. 10, no. 10, pp. 350-357.

Year

2019

ANU Authors

Fields of Research

  • Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)
  • Molecular Targets

Updated:  29 January 2023 / Responsible Officer:  Director (Research Services Division) / Page Contact:  Researchers